Switch to:
GuruFocus has detected 2 Warning Signs with Nivalis Therapeutics Inc $NVLS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Nivalis Therapeutics Inc (NAS:NVLS)
EV-to-EBITDA
0.49 (As of Today)

EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA. As of today, Nivalis Therapeutics Inc's enterprise value is $-16.20 Mil. Nivalis Therapeutics Inc's earnings before depreciation and amortization for the trailing twelve months (TTM) ended in Mar. 2017 was $-32.82 Mil. Therefore, Nivalis Therapeutics Inc's EV/EBITDA ratio for today is 0.49.

NVLS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0   Max: 0.89
Current: 0.49

0
0.89

During the past 5 years, the highest EV/EBITDA Ratio of Nivalis Therapeutics Inc was 0.89. The lowest was 0.00. And the median was 0.00.

NVLS's EV-to-EBITDA is ranked higher than
94% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. NVLS: 0.49 )

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

As of today, Nivalis Therapeutics Inc's stock price is $2.33. Nivalis Therapeutics Inc's earnings per share for the trailing twelve months (TTM) ended in Mar. 2017 was $-2.10. Therefore, Nivalis Therapeutics Inc's P/E Ratio for today is .

The "classic" EV/EBITDA ratio is much better in capturing debt and net cash than the P/E Ratio.


Definition

Nivalis Therapeutics Inc's EV/EBITDA for today is calculated as:

EV/EBITDA=Enterprise Value (Today)/Earnings Before Depreciation and Amortization (TTM)
=-16.195/-32.823
=0.49

Nivalis Therapeutics Inc's current Enterprise Value is $-16.20 Mil.
Nivalis Therapeutics Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Mar. 2017 was -8.56 (Jun. 2016 ) + -7.51 (Sep. 2016 ) + -7.785 (Dec. 2016 ) + -8.968 (Mar. 2017 ) = $-32.82 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

Nivalis Therapeutics Inc's P/E Ratio for today is calculated as:

P/E Ratio=Share Price (Today)/Earnings Per Share (TTM)
=2.33/-2.1
=

Nivalis Therapeutics Inc's share price for today is $2.33.
Nivalis Therapeutics Inc's Earnings Per Share for the trailing twelve months (TTM) ended in Mar. 2017 was -0.55 (Jun. 2016 ) + -0.48 (Sep. 2016 ) + -0.5 (Dec. 2016 ) + -0.57 (Mar. 2017 ) = $-2.10.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Study has found that the companies with the lowest EV/EBITDA outperforms companies measured as cheap by other ratios such as P/E Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Related Terms

Enterprise Value, Earnings Before Depreciation and Amortization, P/E Ratio


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Nivalis Therapeutics Inc Annual Data

Dec12Dec13Dec14Dec15Dec16
ev2ebitda 0.000.000.000.000.000.000.000.00-1.420.82

Nivalis Therapeutics Inc Quarterly Data

Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16Mar17
ev2ebitda 0.000.00-6.35-5.49-1.420.600.09-1.960.820.21
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK